Today: 19 May 2026
Browse Category

NASDAQ:PRAX 16 October 2025 - 14 January 2026

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Shares of Praxis Precision Medicines rose about 8% to $303.23 by mid-afternoon Wednesday after the company named epilepsy specialist Dr. Orrin Devinsky as head of clinical strategy. Investors are watching two FDA drug applications set for mid-February. Praxis recently raised $575 million in a public offering. The broader biotech sector outperformed the market, while major indexes fell.
14 January 2026
·
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines shares jumped 13.25% to $304.58 Monday after the FDA granted Breakthrough Therapy Designation to ulixacaltamide for essential tremor. The company plans to file a New Drug Application in early 2026. BTIG raised its price target on PRAX to $843 from $507. The stock slipped about 1% in after-hours trading.
30 December 2025
···
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines shares jumped 13% to $304.58 after the FDA granted Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The stock traded between $318.08 and $275.00 during the session. Praxis said it plans to file a New Drug Application in early 2026. Analyst BTIG raised its price target on Praxis to $843.
30 December 2025
··
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines shares traded near $265 on December 9, 2025, up over 500% in three months and close to a 52-week high of $278, giving the company a $6.6 billion market cap. The surge followed positive Phase 3 results for ulixacaltamide in essential tremor, new bullish analyst targets, and increased volatility after a short-seller attack.
9 December 2025
·
Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines shares surged 30.5% to close at $247.99 on December 5, hitting a new 52-week high after positive epilepsy trial results and a favorable FDA pre-NDA meeting. The company’s market cap reached about $6.2 billion. PRAX stock has gained over 500% in three years but remains down 72% over five years. Wall Street sentiment is mostly positive, though some skepticism remains.
6 December 2025
·
Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

Treasure Global (NASDAQ:TGL) surged about 276% on December 5, 2025, after a 1-for-20 reverse stock split and news of an acquisition. SMX (NASDAQ:SMX) jumped 135%, and Wheeler Real Estate Investment Trust (NASDAQ:WHLR) gained 98%. The S&P 500, Nasdaq 100, and Dow all closed higher, but small- and mid-cap stocks saw the largest percentage moves.
6 December 2025
············
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines shares jumped nearly 40% intraday on December 5 after its pivotal epilepsy trial was stopped early for efficacy and the company reported a positive pre-NDA meeting with the FDA for its essential tremor drug. By late morning, PRAX traded around $265–266, hitting a new 52-week high and pushing its market cap above $1.1 billion. The stock is up over 200% year-to-date.
5 December 2025
·
Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Praxis Precision Medicines shares traded around $189.97 early December 5 after surging on positive FDA feedback for its essential tremor drug and new data in rare epilepsies. The stock swung between $180.25 and $305.55 intraday, with a market cap near $1.1 billion. PRAX has gained over 1,700% in 12 months, but remains volatile amid short-seller pressure and ongoing losses.
5 December 2025
·
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares jumped 180% to $162 on Oct. 16 after its lead drug, ulixacaltamide, met all key endpoints in two Phase 3 trials for essential tremor. The rally added nearly $3 billion to the company’s market cap. Praxis announced a $525 million public offering to fund commercialization and pipeline expansion. Analyst price targets surged, with several now above $250.
17 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares soared 183% to $162.71 on Thursday after its drug ulixacaltamide met all key goals in a Phase 3 trial for essential tremor. The results showed significant improvement in patient function and no serious side effects. The company plans to seek FDA approval by early 2026 and launched a public stock offering to fund commercialization.
17 October 2025
·
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis shares soared nearly 180% premarket Oct. 16 after positive Phase 3 results for ulixacaltamide in essential tremor, hitting a new 52-week high. The drug met all primary and secondary endpoints in two trials and showed no serious safety issues. Praxis plans to seek FDA approval by early 2026. The company reported a Q2 net loss of $71.1M but held $446M in cash at mid-2025.
16 October 2025
··

Stock Market Today

  • Melius Research boosts Intel stock price target to $150 amid market volatility
    May 19, 2026, 4:11 PM EDT. Intel (INTC) shares have fallen 19.17% since their May 11 peak of $129.44, currently trading at $104.62. Despite recent positive news, including Intel's chip manufacturing deals with Apple and expanded partnerships with Google, semiconductor stocks faced pressure due to macro events such as President Trump's China visit without major chip agreements. Melius Research analyst Benjamin Reitzes raised Intel's price target sharply to $150 from $100, signaling a 43.37% upside and maintaining a buy rating. Reitzes, with a 62% success rate, sees strong long-term growth in AI and memory chip segments. However, this target stands out against a consensus average of $87.09 and limited buy recommendations, reflecting market skepticism and Bank of America's bearish stance.

Latest articles

Wall Street Just Got Hit by the Bond Market Again — What Traders Are Watching Next

Wall Street Just Got Hit by the Bond Market Again — What Traders Are Watching Next

19 May 2026
The S&P 500 fell 0.55%, Nasdaq lost 0.72%, and Dow dropped 0.47% Tuesday as Treasury yields climbed, with the 10-year at 4.67% and the 30-year at 5.18%, its highest since 2007. Brent crude hovered near $111. Home Depot rose after earnings, while Akamai slid on a $2.6 billion convertible-note offering. Investors watched Nvidia ahead of its results.
Intel Stock Bounces as Wall Street Rethinks AI Narrative

Intel Stock Bounces as Wall Street Rethinks AI Narrative

19 May 2026
Intel shares climbed 3.3% to $111.69 Tuesday afternoon, rebounding after five sessions of losses as Citi and Benchmark raised price targets, citing stronger CPU demand. Trading volume topped 112 million shares. The move came ahead of Nvidia’s earnings, which options traders expect to trigger a major market shift. Intel CEO Lip-Bu Tan was set to speak at a J.P. Morgan conference later in the day.
Pinterest shares erase post-earnings gains

Pinterest shares erase post-earnings gains

19 May 2026
Pinterest shares fell about 6% Tuesday, trading at $18.74 by 3:05 p.m. EDT, erasing gains from its May earnings rally. The drop outpaced declines in Meta, Snap, and Reddit as the Nasdaq and S&P 500 also slipped. Pinterest reported Q1 revenue of $1.008 billion, up 18%, with a net loss of $74 million. The company forecast Q2 revenue above analyst expectations.
Go toTop